Cannell & Spears’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $54.1M | Sell |
248,683
-20,949
| -8% | -$4.65M | 1.06% | 26 |
|
|
2025
Q4 | $61.6M | Sell |
269,632
-15,394
| -5% | -$3.51M | 1.15% | 23 |
|
|
2025
Q3 | $66M | Sell |
285,026
-55,406
| -16% | -$11.3M | 1.24% | 20 |
|
|
2025
Q2 | $63.2M | Buy |
340,432
+78,809
| +30% | +$14.6M | 1.28% | 20 |
|
|
2025
Q1 | $54.8M | Buy |
261,623
+39,140
| +18% | +$7.61M | 1.18% | 23 |
|
|
2024
Q4 | $39.5M | Sell |
222,483
-1,327
| -0.6% | -$244K | 0.81% | 40 |
|
|
2024
Q3 | $44.2M | Sell |
223,810
-46,578
| -17% | -$8.69M | 0.87% | 36 |
|
|
2024
Q2 | $46.4M | Sell |
270,388
-1,635
| -0.6% | -$271K | 0.96% | 35 |
|
|
2024
Q1 | $49.5M | Buy |
272,023
+264,906
| +3,722% | +$45.7M | 1.02% | 30 |
|
|
2023
Q4 | $1.1M | Hold |
7,117
| – | – | 0.09% | 92 |
|
|
2023
Q3 | $1.06M | Buy |
7,117
+17
| +0.2% | +$2.5K | 0.09% | 83 |
|
|
2023
Q2 | $957K | Sell |
7,100
-389
| -5% | -$57K | 0.08% | 97 |
|
|
2023
Q1 | $1.19M | Buy |
7,489
+99
| +1% | +$15.1K | 0.11% | 84 |
|
|
2022
Q4 | $1.19M | Buy |
7,390
+50
| +0.7% | +$7.67K | 0.11% | 86 |
|
|
2022
Q3 | $985K | Hold |
7,340
| – | – | 0.1% | 89 |
|
|
2022
Q2 | $1.12M | Hold |
7,340
| – | – | 0.1% | 88 |
|
|
2022
Q1 | $1.19M | Sell |
7,340
-460
| -6% | -$66.8K | 0.09% | 93 |
|
|
2021
Q4 | $1.06M | Hold |
7,800
| – | – | 0.07% | 101 |
|
|
2021
Q3 | $841K | Hold |
7,800
| – | – | 0.06% | 106 |
|
|
2021
Q2 | $879K | Buy |
7,800
+389
| +5% | +$43.8K | 0.06% | 105 |
|
|
2021
Q1 | $802K | Hold |
7,411
| – | – | 0.06% | 104 |
|
|
2020
Q4 | $794K | Hold |
7,411
| – | – | 0.07% | 100 |
|
|
2020
Q3 | $649K | Buy |
7,411
+700
| +10% | +$65.9K | 0.06% | 106 |
|
|
2020
Q2 | $659K | Buy |
6,711
+55
| +0.8% | +$4.84K | 0.07% | 101 |
|
|
2020
Q1 | $507K | Sell |
6,656
-102
| -2% | -$8.69K | 0.06% | 109 |
|
|
2019
Q4 | $598K | Buy |
6,758
+102
| +2% | +$8.47K | 0.06% | 92 |
|
|
2019
Q3 | $504K | Sell |
6,656
-3,606
| -35% | -$247K | 0.06% | 99 |
|
|
2019
Q2 | $746K | Buy |
10,262
+7,106
| +225% | +$559K | 0.09% | 80 |
|
|
2019
Q1 | $254K | Hold |
3,156
| – | – | 0.03% | 146 |
|
|
2018
Q4 | $291K | Hold |
3,156
| – | – | 0.04% | 125 |
|
|
2018
Q3 | $298K | Hold |
3,156
| – | – | 0.04% | 137 |
|
|
2018
Q2 | $292K | Hold |
3,156
| – | – | 0.04% | 134 |
|
|
2018
Q1 | $299K | Hold |
3,156
| – | – | 0.04% | 134 |
|
|
2017
Q4 | $305K | Sell |
3,156
-60
| -2% | -$5.66K | 0.04% | 138 |
|
|
2017
Q3 | $286K | Hold |
3,216
| – | – | 0.03% | 124 |
|
|
2017
Q2 | $233K | Hold |
3,216
| – | – | 0.03% | 131 |
|
|
2017
Q1 | $210K | Hold |
3,216
| – | – | 0.03% | 124 |
|
|
2016
Q4 | $201K | Hold |
3,216
| – | – | 0.03% | 128 |
|
|
2016
Q3 | $203K | Sell |
3,216
-172
| -5% | -$11.1K | 0.03% | 122 |
|
|
2016
Q2 | $210K | Buy |
+3,388
| New | +$206K | 0.03% | 118 |
|
|
2016
Q1 | – | Sell |
-4,175
| Closed | -$247K | – | 125 |
|
|
2015
Q4 | $247K | Hold |
4,175
| – | – | 0.03% | 110 |
|
|
2015
Q3 | $227K | Sell |
4,175
-2,738
| -40% | -$178K | 0.03% | 121 |
|
|
2015
Q2 | $464K | Sell |
6,913
-71
| -1% | -$4.63K | 0.05% | 99 |
|
|
2015
Q1 | $409K | Sell |
6,984
-75
| -1% | -$4.53K | 0.05% | 99 |
|
|
2014
Q4 | $462K | Hold |
7,059
| – | – | 0.05% | 98 |
|
|
2014
Q3 | $408K | Buy |
7,059
+60
| +0.9% | +$3.33K | 0.05% | 98 |
|
|
2014
Q2 | $395K | Sell |
6,999
-278
| -4% | -$14.6K | 0.05% | 101 |
|
|
2014
Q1 | $374K | Buy |
7,277
+1,190
| +20% | +$60.1K | 0.05% | 84 |
|
|
2013
Q4 | $321K | Hold |
6,087
| – | – | 0.04% | 95 |
|
|
2013
Q3 | $272K | Sell |
6,087
-100
| -2% | -$4.43K | 0.04% | 105 |
|
|
2013
Q2 | $256K | Buy |
+6,187
| New | +$271K | 0.04% | 79 |
|
Other funds holding ABBV
VCM
VPM
Cannell & Spears's ABBV Position: Q1 2026 in Review
Cannell & Spears reduced its AbbVie (ABBV) stake by 7.8% in Q1 2026, selling an estimated $4.65M and leaving 248,683 shares worth $54.1M. The position accounts for 1.06% of the portfolio, ranked #26.
Cannell & Spears first reported a position in ABBV in Q2 2013 and has held it in 51 quarters since. The position peaked at $66M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Cannell & Spears held 248,683 shares of AbbVie worth $54.1M as of Q1 2026.
- Cannell & Spears sold 20,949 AbbVie shares in Q1 2026, an estimated $4.65M.
- AbbVie made up 1.06% of Cannell & Spears's portfolio in Q1 2026, its #26 holding.
- Cannell & Spears first reported a position in AbbVie in Q2 2013 and has held it in 51 quarters since.
- Cannell & Spears's AbbVie position peaked at $66M in Q3 2025.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Cannell & Spears's 13F filing for Q1 2026, filed 14 May 2026.